Amplify Weight Loss Drug & Treatment ETF (THNR) — Titan Protect Analysis

THNR

Amplify Weight Loss Drug & Treatment ETF

Financial · ·

$24.31

Data: 2026-06-03

✗ ETHICAL FAIL

UNKNOWN MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

N/A

Total market value of the company

Trailing P/E

19.77

Reasonably valued

Forward P/E

N/A

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

N/A

Consensus view from ? analysts covering this stock

About Amplify Weight Loss Drug & Treatment ETF

The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies expected to economically benefit from weight loss drug development. The index includes pharmaceutical manufacturers, manufacturers of combination therapies and telehealth providers who provide access to Amylin agonists and analogs or GLP-1 agonists and analogs, including dual GLP-1 agonists and analogs. The fund is n

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

FAIL

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.042

Positive but modest risk-adjusted returns

Kelly Fraction

0.0015

Marginal edge — very small allocation suggested

Calmar Ratio

-0.033

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-1.1%

Historical annualised return based on price data

Max Drawdown

-32.5%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$27.28

11% below the year high

52W Low

$21.70

12% above the year low

Avg Volume

1,174

Average daily shares traded — higher means easier to buy and sell

Short Ratio

N/A

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

169.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$N/A

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

N/A

Loss-making — spending exceeds revenue after all costs

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go